Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BCAB
- Price
- 0.32
- Stock movement up
- +0.01 (4.16%)
- Company name
- Bioatla Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 15.24M
- Ent value
- -2.00M
- Price/Sales
- 1.20
- Price/Book
- 0.66
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -90.59%
- 3 year return
- -59.96%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-14
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
BCAB does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.20 |
| Price to Book | 0.66 |
| EV to Sales | -0.16 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 48.35M |
| EPS (TTM) | -1.69 |
| FCF per share (TTM) | -1.76 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 12.71M |
| Gross profit (TTM) | 11.87M |
| Operating income (TTM) | -86.23M |
| Net income (TTM) | -81.82M |
| EPS (TTM) | -1.69 |
| EPS (1y forward) | -1.31 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 93.41% |
| Operating margin (TTM) | -678.70% |
| Profit margin (TTM) | -643.92% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 56.52M |
| Net receivables | 0.00 |
| Total current assets | 60.57M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 62.24M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 1.25M |
| Total current liabilities | 19.46M |
| Total liabilities | 39.27M |
| Shareholder's equity | 22.97M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -85.08M |
| Capital expenditures (TTM) | 8.00K |
| Free cash flow (TTM) | -85.08M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -356.22% |
| Return on Assets | -131.46% |
| Return on Invested Capital | -337.82% |
| Cash Return on Invested Capital | -351.31% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.31 |
| Daily high | 0.32 |
| Daily low | 0.30 |
| Daily Volume | 357K |
| All-time high | 70.91 |
| 1y analyst estimate | 9.00 |
| Beta | 1.02 |
| EPS (TTM) | -1.69 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 May 2025 |
Downside potential
Loading...
Downside potential data
| BCAB | S&P500 | |
| Current price drop from All-time high | -99.56% | -12.04% |
| Highest price drop | -99.62% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -80.92% | -11.07% |
| Avg time to new high | 45 days | 12 days |
| Max time to new high | 1024 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
15.24M
Marketcap category
Small-cap
Description
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
Employees
65
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page